{
    "medicine_id": "6eb5018973b7dc080eee172ab205ec0c218ad089",
    "platform_id": "DB04866",
    "metadata": {
        "name": "Synribo 3 5 mg 1mL Injection powder lyophilized for solution",
        "composition": "3 5 mg 1mL Halofuginone",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of scleroderma cancer and restenosis",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Halofuginone a fully synthetic small molecule is a potent and selective regulator of stromal cell activation cell migration and Collagen type I synthesis a process that has been identified as a master switch in the body s tissue repair process",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Halofuginone"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Halofuginone"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Halofuginone"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Halofuginone"
                    },
                    {
                        "drugbank-id": "DB00282",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Halofuginone is combined with Pamidronic acid"
                    },
                    {
                        "drugbank-id": "DB00399",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Halofuginone is combined with Zoledronic acid"
                    },
                    {
                        "drugbank-id": "DB00630",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Halofuginone is combined with Alendronic acid"
                    },
                    {
                        "drugbank-id": "DB00710",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Halofuginone is combined with Ibandronate"
                    },
                    {
                        "drugbank-id": "DB00720",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Halofuginone is combined with Clodronic acid"
                    },
                    {
                        "drugbank-id": "DB00884",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Halofuginone is combined with Risedronic acid"
                    },
                    {
                        "drugbank-id": "DB01077",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Halofuginone is combined with Etidronic acid"
                    },
                    {
                        "drugbank-id": "DB01133",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Halofuginone is combined with Tiludronic acid"
                    },
                    {
                        "drugbank-id": "DB06255",
                        "description": "The risk or severity of jaw osteonecrosis and anti angiogenesis can be increased when Halofuginone is combined with Incadronic acid"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}